Publications by authors named "M DeMarco"
Conscience is the indestructible core of one's personal identity and their sense of agency in the world. When it passes judgment against them, it generates inner conflict (i.e.
View Article and Find Full Text PDFBackground: We describe the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core major activities from October 2004 to March 2024, including biobanking ADNI cerebrospinal fluid (CSF), plasma, and serum biofluid samples, biofluid analyses for Alzheimer's disease (AD) biomarkers in the Biomarker Core and various non-ADNI laboratories, and continuous assessments of pre-analytics.
Results: Validated immunoassay and mass spectrometry-based assays were performed in CSF with a shift to plasma, a more accessible biofluid, as qualified assays became available. Performance comparisons across different CSF and plasma AD biomarker measurement platforms have enriched substantially the ADNI participant database enabling method performance determinations for AD pathology detection and longitudinal assessments of disease progression.
Background & Aims: Endoscopic retrograde cholangiopancreatography (ERCP)-related adverse events (AEs) are associated with morbidity, mortality, and health care expenditure. We aimed to assess incidences and comparisons of ERCP AEs.
Methods: We included studies performed after 2000 reporting on ERCP AEs from database inception through March 12, 2024.
Article Synopsis
- - Varoglutamstat is a new small molecule being tested for early Alzheimer's disease, targeting glutaminyl cyclase to potentially reduce toxic forms of amyloid-β and neuroinflammatory cytokines.
- - The VIVA-MIND trial is structured in two phases, with phase 2A focusing on determining the safe dose and phase 2B evaluating the drug's effectiveness and long-term safety through a 72-week period.
- - The trial's design allows for continuous safety assessments and adaptive decision-making based on cognitive function and electroencephalogram changes, aiming to confirm varoglutamstat's unique ability to tackle several aspects of Alzheimer's pathology.